COPENHAGEN, Aug 11: Denmark’s Novo Nordisk could be a few months away from dropping a drug expected to replace crucial blood treatment Novoseven and seen as a potential blockbuster, the company said on Friday. The world’s biggest insulin producer said it could be forced to drop haemophilia drug candidate, vatreptacoq alfa, unless phase III data proved very favorable. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel